Iopasentis

Iopamidol, the active ingredient in Iopasentis, is an iodinated contrast media presented as a sterile injectable solution for intra‑arterial and intravenous use. It provides radiopaque contrast for diagnostic imaging procedures in patients undergoing angiography, CT or vascular imaging.

GNH USA supplies Iopasentis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Iopasentis is an iodinated contrast agent used in diagnostic imaging to enhance visualization of vascular and tissue structures. - Angiography: improves delineation of blood vessels for accurate assessment. - Computed tomography (CT) imaging: increases contrast between structures, aiding lesion detection. - Vascular imaging: highlights arterial and venous anatomy for precise diagnosis.

Iopasentis may cause a range of adverse reactions following administration.

Common Side Effects: - Warmth or flushing sensation at injection site. - Metallic taste in the mouth. - Nausea or mild vomiting. - Headache or dizziness. - Transient urticaria or mild skin rash. - Mild hypotension.

Serious or Rare Side Effects: - Anaphylactoid or severe allergic reaction (anaphylaxis). - Contrast‑induced nephropathy leading to acute kidney injury. - Severe hypotension or cardiovascular collapse. - Cardiac arrhythmias. - Seizures. - Thyroid dysfunction (hyper‑ or hypothyroidism).

Prior to using Iopasentis, clinicians should evaluate patient risk factors and follow safety measures. - Renal function assessment: check baseline creatinine and eGFR. - Allergy history: screen for iodine or contrast media hypersensitivity. - Hydration: ensure adequate fluid intake to reduce nephrotoxicity. - Concurrent nephrotoxic drugs: avoid or monitor NSAIDs, aminoglycosides, etc. - Pregnancy and lactation: use only if clearly necessary. - Store at below 25°C: keep in original container, protect from light and moisture.

Iopasentis can interact with certain medications, requiring caution.

Major Interactions (Avoid): - Metformin: risk of lactic acidosis; discontinue before contrast administration. - Iodine‑containing drugs (e.g., amiodarone): may exacerbate thyroid dysfunction. - Nephrotoxic agents (e.g., NSAIDs, aminoglycosides): increase risk of renal injury.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask contrast‑induced tachycardia. - ACE inhibitors/ARBs: may affect renal function; monitor kidney parameters. - Diuretics: may alter intravascular volume; observe hemodynamic status.